Targeted Oncologic Therapies Demand New Approach to Phase II/III Trials

Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet